Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
AffiliationDivision of Cancer Sciences, University of Manchester, Manchester, UK.
MetadataShow full item record
CitationPhillips EH, Illidge TM. Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma? Br J Haematol. 2020.
JournalBritish Journal of Haematology
- Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
- Authors: Hu B, Jacobs R, Ghosh N
- Issue date: 2018 Dec
- Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
- Authors: Merryman RW, Armand P, Wright KT, Rodig SJ
- Issue date: 2017 Dec 12
- Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
- Authors: Matsuki E, Younes A
- Issue date: 2016 Jun
- Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.
- Authors: Veldman J, Visser L, Berg AVD, Diepstra A
- Issue date: 2020 Jan
- Immune checkpoint blockade for hematologic malignancies: a review.
- Authors: Pianko MJ, Liu Y, Bagchi S, Lesokhin AM
- Issue date: 2017